GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments. The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners [...]

• 20View 3 Comments...http://clsdf.com/2005/09/catching-the-eye-of-costal-vc%e2%80%99s-and-ib%e2%80%99s/Catching+the+Eye+of+Costal+VC%E2%80%99s+and+IB%E2%80%99s2005-09-25+20%3A35%3A00admin

Replidyne continues their charge towards the planned 4Q05 NDA filing for Faropenem, an antibiotic for the treatment of respiratory tract infections. To aid these efforts the company has just closed on a $62.5 million Series D financing led by several new investors including: Duquesne Capital Management, Healthcare Investment Partners and MDS Life Sciences. Also participating [...]

• 19View 6 Comments...http://clsdf.com/2005/09/replidyne-%e2%80%93-nda-or-bust/Replidyne+%E2%80%93+NDA+or+Bust%212005-09-10+05%3A25%3A00admin